This is a multifaceted program consisting of five projects designed to increase our understanding of the cellular and molecular features of multi le myeloma and its genesis and relationship to monoclonalgammopathy of undetermined significance (MUU S). Dr. Kyle (Project I) will determine the prevalence of MGUS in Olmsted County. He will also follow the survivors of the Southeastern Minnesota MGUS cohort and all subsequently diagnosed cases in this population to assess predictors of outcome. Dr. Lust (Project II) will investigate the role of IL-1 beta on the expression and function of adhesion molecules in myeloma. Human myeloma cell lines that differ with respect to IL-1beta expression will be utilized as a model to study IL-lbeta in SCID mice. He will investigate the effects of IL-1beta and IL-1beta inhibitors on adhesion molecule expression on patient myeloma cells and on the adhesion of patient myeloma cells to bone marrow stromal cells. Dr. Witzig (Project III) will characterize the clonally related B cells found in MGUS and myeloma and investigate their capacity to be differentiated to plasma cells. He will determineheparan sulfate proteoglycan expression and the role of fibroblastic growth factors (FGF) and FGF receptors in the proliferation and apoptosis of myeloma cells. Dr. Van Ness (Project IV) will focus on the relationship between genetic alterations and apoptosis in myeloma cells. He will use myeloma cell lines to examine the effects of genetic alterations in Ras, p53, Rb, and PTP1C (SHP-1) on cell proliferation, apoptotic signaling, and therapeutic response. He will determine how genetic alterations affect apoptosis in myeloma by determining how expression of Bcl-2, BclXl, bad, and bax are regulated to enhance or protect cells from apoptosis. He will also study how apoptosis is mediated by therapeutic agents such as steroids, cytokines, alkylating, and antimitotic agents in myeloma cells with different genetic alterations. Dr. Jelinek (Project V) will focus on IL-6 mediated growth control of myeloma cells. The importance of JAK/STAT and Ras/MAPK pathways will be studied. She will identify and characterize the genetic targets of IL-6 signal transduction pathway (s) in myeloma by utilizing differential display reverse transcription polymerase chain reaction and cDNA array analysis. Core A will centralize cell collection and provide pure preparations of myeloma cells for each project. Core B will play a key role in project design and will provide statistical analysis of individual project data. It will also provide a central resource for sharing an coordinating data between the projects. The major aim of this Program Project is to obtain a better understanding of the pathophysiology of the monoclonal gammopathies. We believe that these results will ultimately translate into improved and novel therapeutic strategies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Wu, Roy S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Lwin, S T; Fowler, J A; Drake, M T et al. (2017) A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo. Mol Cancer 16:49
Gonsalves, W I; Rajkumar, S V; Dispenzieri, A et al. (2017) Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia 31:130-135
Mullikin, Trey C; Rajkumar, S Vincent; Dispenzieri, Angela et al. (2016) Clinical characteristics and outcomes in biclonal gammopathies. Am J Hematol 91:473-5
Gonsalves, Wilson I; Timm, Michael M; Rajkumar, S Vincent et al. (2016) The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Leuk Res 44:32-9
Kaufman, Gregory P; Dispenzieri, Angela; Gertz, Morie A et al. (2015) Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. Am J Hematol 90:181-6
Gonsalves, W I; Leung, N; Rajkumar, S V et al. (2015) Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J 5:e296
Cesarman-Maus, Gabriela; Braggio, Esteban; Lome-Maldonado, Carmen et al. (2014) Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin. Thromb Res 133:606-9
Landgren, O; Graubard, B I; Katzmann, J A et al. (2014) Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia 28:1537-42
Kumar, S K; Dispenzieri, A; Lacy, M Q et al. (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28:1122-8
Gonsalves, Wilson I; Rajkumar, S Vincent; Go, Ronald S et al. (2014) Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood 124:907-12

Showing the most recent 10 out of 365 publications